Industry Supported Session
The past decade has been transformative for the treatment of myasthenia gravis. In this symposium, we take stock of our current understanding of the disease and survey the current treatment landscape, with a focus on the evolving role of FcRn inhibitors and their place in therapy. We will explore promising developments and emerging approaches such as complement-targeted and CAR-T cell therapies.
Join us for an exciting session with an updated take on myasthenia gravis and its present – and future – treatment.
This program was developed and planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.
